Article History
Accepted: 22 November 2022
First Online: 1 March 2023
Declarations
:
: Mazen Noureddin has been on the advisory board/consultant for 89BIO, Altimmune, Gilead, cohBar, CytoDyn, Intercept, Pfizer, Novo Nordisk, Blade, EchoSens, Fractyl, Madrgial, NorthSea, Prespecturm, Terns, Sami-Sabina group, Siemens and Roche diagnostic; MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Madrigal, Novartis, Pfizer, Shire, Viking, and Zydus; MN is a shareholder or has stocks in Anaetos, Chrownwell, Ciema, Rivus Pharma, and Viking.Emily Truong, Cheng Han, and Mark Muthiah declare that they have no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.